Wenfeng Fang

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Brain Metastases

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Lan-Lan Pang, Yi-Hua Huang, Weitao Zhuang, Yaxiong Zhang, Jun Liao, Yue Hao, Feng Hao, Guoqian Wang, Ze-Xin Chase Chen, Yu Zhu, Mengzhen Li, Zhengbo Song, Bo Peng Deng, Jing Li, Li Zhang, Wenfeng Fang
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (12) (2024)
Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Lan-Lan Pang, Yi-Hua Huang, Weitao Zhuang, Yaxiong Zhang, Jun Liao, Yue Hao, Feng Hao, Guoqian Wang, Ze-Xin Chase Chen, Yu Zhu, Mengzhen Li, Zhengbo Song, Bo Peng Deng, Jing Li, Li Zhang, Wenfeng Fang
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (12) (2024)
Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiao-Xu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xue-Ding Wang, Li Zhang
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Lan-Lan Pang, Yi-Hua Huang, Weitao Zhuang, Yaxiong Zhang, Jun Liao, Yue Hao, Feng Hao, Guoqian Wang, Ze-Xin Chase Chen, Yu Zhu, Mengzhen Li, Zhengbo Song, Bo Peng Deng, Jing Li, Li Zhang, Wenfeng Fang
Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Shaodong Hong, Ya-Xiong Zhang, Gengsheng Yu, Peijian Peng, Jiewen Peng, Jun Jia, Xuan Wu, Yan Huang, Yunpeng Yang, Qing Lin, Xuping Xi, Mingjun Xu, Dongping Chen, Xiaojun Lu, Ren-Sheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao, Wenfeng Fang, Li Zhang
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (29) (2021)
Zhonghan Zhang, Yang Zhang, Fan Luo, Yuxiang Ma, Wenfeng Fang, Jing Zhan, Su Li, Yunpeng Yang, Yuanyuan Zhao, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Shen Zhao, Yan Huang, Hongyun Zhao, Li Zhang
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. Clinical and translational medicine 10 (2) (2020)